52 results about "Fibromyalgia" patented technology

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

Non-pharmaceutical systems and methods of treating the symptoms of fibromyalgia are described. The method includes administering a therapeutically effective amount of a sensory stimulus to a person, wherein the sensory stimulus includes one or more visual stimuli and one or more auditory stimuli.

Provided are methods for treating fibromyalgia or one or more symptoms thereof, that involve the administration of psychedelics, such as psilocybin or a metabolite thereof, and related uses of the psychedelics. The disclosure in some aspects also relates to methods for identifying subjects for treatment of fibromyalgia with administration of psychedelics. In some aspects, the treatment also involves psychotherapy. In some aspects, the subject receiving the treatment is assessed for various indicators, such as observer-rated and subject-reported outcomes, biological and clinical indicators, and combinations thereof.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

Disclosed herein include methods, compositions, and kits suitable for use in treating fibromyalgia. In some embodiments, the method comprises the administration of a composition comprising ketamine, norketamine and a pharmaceutically acceptable salt thereof. In some embodiments, the composition is an extended-release formulation, such as an implant.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. Tire methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and / or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

Provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same for treating drug addiction, drug dependence, drug overdose, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity.

The current disclosure address a need in the art by providing methods and compositions for treating migraines and certain pain-related disorders with a combination therapy. Accordingly, aspects of the disclosure relate to a method for treating a migraine, post-traumatic headache, or chronic pain syndrome patient, the method comprising administering to the patient an effective amount of an insulin growth factor receptor (IGFR) activator and a calcitonin gene-related peptide (CGRP) inhibitor. Further aspects relate to a composition comprising insulin-like growth factor-1 (IGF-1) and a CGRP inhibitor. Also provided are methods for treating fibromyalgia or chronic fatigue syndrome in a patient, the method comprising administering to the patient an effective amount of an insulin growth factor receptor (IGFR) activator.

The invention provides methods, kits and reagents for diagnosing fibromyalgia (FM) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive / indicative of FM in the individual.

Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same to treat drug addiction, drug dependence, drug excess, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity. (I)

The present disclosure relates to diagnostic and therapeutic applications of photobiomodulation and light therapies such as red-light therapy and electrical stimulation devices. Application areas include gut, uterine and other pelvic conditions, back pain, endometriosis, fibromyalgia, etc. The methods and devices disclosed herein are used for delivering targeted therapy using personalized and adjustable treatment protocols which may use features such as real-time monitoring and closed-loop feedback. The devices described herein can be worn discretely to deliver therapy. The present disclosure also includes artificial intelligence and machine learning-based methods for such diagnostic and therapeutic applications.

The present disclosure provides methods of preventing or treating a patient having Long COVID comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti -interleukin-6 (anti-IL-6) antibody. The method described herein can prevent or treat Long COVID associated symptoms or diseases such as postural orthostatic tachycardia syndrome (POTS), brain fog, post-exertional malaise, aerobic metabolism impairment or deficiency, Chronic Fatigue Syndrome (CFS), fibromyalgia, and Mast cell activation syndrome (MCAS).

Provided herein are methods and compositions for a synergistic treatment to improve pathological changes in diseases associated with metabolic syndrome, such as type 2 diabetes, fatty liver, non-alcoholic liver cirrhosis, fibromyalgia Alzheimer's disease and neurodegeneration. The synergistic combination of at least three of the four ingredients including CBD, BC and TB, as well as RP and BC.

Described herein are methods of treating fibromyalgia, comprising administering esreboxetine to a human being in need thereof. Esreboxetine may also be used in the manufacture of a medicament for the treatment of fibromyalgia.

To provide a therapeutic agent for myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) and fibromyalgia.SOLUTION: A therapeutic agent for a disease selected from myalgic encephalomyelitis / chronic fatigue syndrome and fibromyalgia, comprising 2-amino-2 - [2 - (4-heptyloxy-3-trifluoromethylphenyl) ethyl] propane-1, 3-diol or pharmaceutically acceptable salts thereof.SELECTED DRAWING: Figure 1

A composition includes diamine oxidase for use in prevention or treatment of symptoms and disorders caused by fibromyalgia or chronic fatigue syndrome.

The present invention aims to provide a therapeutic agent for myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) and fibromyalgia. A therapeutic agent for a disease selected from myalgic encephalomyelitis / chronic fatigue syndrome, and fibromyalgia, containing 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

The present invention relates to functional foods comprising DAO and their use for the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood, in particular for the prevention or treatment of migraine, chronic fatigue, fibromyalgia, spondylitis and pain caused by muscle contractures.

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

The present invention relates to functional foods comprising DAO and their use for the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood, in particular for the prevention or treatment of migraine, chronic fatigue, fibromyalgia, spondylitis and pain caused by muscle contractures.

The present disclosure pertains to compositions and methods for the treatment and / or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD) / Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and / or physical performance levels and / or decreasing exertion during exercise in a subject by the administration of C5 ketones.

The present invention comprises excluding fibromyalgia patients in clinical studies for patients with lupus, treating the patients for lupus, and increasing the effectiveness of the lupus treatment by excluding patients with fibromyalgia. This makes the SELENA-SLEDAI and BILAG unreliable instruments for assessing the effectiveness of lupus interventions.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the autonomic nervous system. The focused ultrasound signal can have a mechanical index of between about 0.1 to about 5.0 and / or an acoustic pressure of between about 0.1 MPa to about 2.5 MPa. The medical condition can comprise chronic or refractory rhinitis, chronic rhinosinusitis, autonomic instability / autonomic dysfunction, functional gastrointestinal disorders, inflammatory disorders, immune disorders (including improving cancer and infections by neuromodulation of immune function), complex regional pain syndrome, post-traumatic stress disorder (PTSD), anxiety and anxiety-associated disorders, autism, fibromyalgia, uterine function, metabolic disorder, urinary incontinence or binge eating.

The present invention aims to provide a therapeutic agent for myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) and fibromyalgia. A therapeutic agent for a disease selected from myalgic encephalomyelitis / chronic fatigue syndrome, and fibromyalgia, containing 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

The present invention relates to functional foods comprising DAO and their use for the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood, in particular for the prevention or treatment of migraine, chronic fatigue, fibromyalgia, spondylitis and pain caused by muscle contractures.